Securities code: 002551 securities abbreviation: Shenzhen Glory Medical Co.Ltd(002551) Announcement No.: 2022-010 bond Code: 128053 bond abbreviation: Shangrong convertible bond
Shenzhen Glory Medical Co.Ltd(002551)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Notice period
From January 1, 2021 to December 31, 2021.
2. Advance notice
\uf0f0 turning losses into profits \uf0f0 rising in the same direction \uf0fe falling in the same direction
The current reporting period of the project is the same period of last year
Profit attributable to listed companies: 40 million yuan to 60 million yuan
Net profit of shareholders: 162.1366 million yuan, a decrease of 62.99% – 75.33% over the same period of last year
Profit after deducting non recurring losses: 11.1747 million yuan to 31.1747 million yuan
Net profit after profit: 153.8193 million yuan, down 79.73% – 92.74% over the same period of last year
Basic earnings per share: 0.0482 yuan / share – 0.0723 yuan / share earnings: 0.1952 yuan / share
2、 Communication with accounting firms
The financial data related to this performance forecast has not been pre audited by certified public accountants, but the company has pre communicated with the accounting firm on this performance forecast. As of the disclosure date of this performance forecast, there is no significant difference between the two sides in this performance forecast, and the specific data shall be subject to the audit results.
3、 Explanation of performance change reasons
1. During the reporting period, the main products of the company’s holding subsidiaries Hefei pulde Medical Products Co., Ltd. (hereinafter referred to as “pulde medical”) and pulde Holding Co., Ltd. (hereinafter referred to as “pulde holding”) were disposable medical protection products and disposable medical consumables. Due to the difficulty of order shipment caused by the shortage of international transportation, the sales volume of the company’s products was seriously affected, the transportation cost increased, and the product price was adjusted due to the failure of delivery, resulting in a significant year-on-year decrease in the net profit of pulde medical and pulde holdings in the reporting period. 2. Due to the continuous impact of the epidemic in some regions, the progress of the company’s medical professional engineering projects did not meet the expectations, resulting in the project can not be completed and settled on time, various costs increased, and the net profit of medical professional engineering projects decreased significantly in the reporting period.
3. In accordance with the accounting standards for Business Enterprises No. 8 – asset impairment and relevant accounting policies, combined with the actual operation of the company and the operation and financial status of various assets of the company, and based on the principle of prudence, the company conducted a preliminary impairment test on relevant assets with signs of impairment (falling price) during the reporting period, It is estimated that the provision for asset impairment (depreciation) is about 30 million yuan to 40 million yuan (the final data is subject to the audit report).
4、 Other relevant instructions
1. This performance forecast is the result of the preliminary calculation of the company’s financial department and has not been audited by the audit institution;
2. The specific financial data of 2021 annual performance will be disclosed in detail in the 2021 annual report. The company will timely disclose information in strict accordance with the provisions and requirements of relevant laws and regulations. Please pay attention to investment risks.
It is hereby announced.
Shenzhen Glory Medical Co.Ltd(002551) board of directors
January 29, 2022
